Role of 18F-FDG PET/CT in establishing new clinical and therapeutic modalities in lung cancer. A short review

Interventions of Advanced Lung Cancer Patient Receiving Chemotherapy by Computed Tomography Image Information Data Analysis-Based Soothing Care Plans

The objective of this study was to investigate the intervention effect of computed tomography (CT) image information data on patients with advanced lung cancer treated with chemotherapy under palliative care program. The research subjects were 60 patients with advanced lung cancer who received palliative care in our hospital from January 1, 2019, to January 1, 2021. All patients were grouped according to the evaluation criteria of solid tumor efficacy, including 28 patients in the remission group and 32 patients in the nonremission group. Texture analysis was performed on the CT images of the two groups of patients. The gray-scale cooccurrence matrix parameters, the maximum diameter of the lesion, and the CT value of the CT images of the two groups of patients before and after palliative care were compared. The results showed that after the palliative care, the combined mean, combined energy, and inverse moment of the three gray cooccurrence matrix parameters of the two groups of patients were decreased, and the combined entropy and contrast were increased. The absolute value of the gray-scale cooccurrence matrix Δ parameter of the patients in the remission group was greater than that in the nonremission group. The Δ combined entropy, Δ contrast, and Δ correlation of the two groups of patients were significantly different, and the difference in Δ contrast was the largest. It suggested that the gray-scale cooccurrence matrix parameter can evaluate the effect of soothing care, and the contrast was the best evaluation parameter. The maximum diameter of the lesions in the remission group before and after palliative care was reduced by 1.23 cm, and the degree of reduction was significantly better. The CT value was reduced by 6.22 HU, and the degree of reduction was significantly higher than that in the nonremission group. There was a significant difference in the data between the two groups (P < 0.05). Therefore, the CT image information data had a better evaluation effect on patients with advanced lung cancer under the palliative care program and can be applied to the clinical evaluation of the palliative care effect, which had good clinical value.

Efficacy Evaluation of Zoledronic Acid Combined with Chemotherapy in the Treatment of Lung Cancer Spinal Metastases on Computed Tomography Images on Intelligent Algorithms

To analyze the effectiveness and safety of zoledronic acid combined with chemotherapy for lung cancer spinal metastases, 96 patients with lung cancer spinal metastases were averagely classified into the experimental group (gemcitabine, cisplatin, and zoledronic acid) and the control group (gemcitabine and cisplatin). An optimized noise variance estimation algorithm (OMAPB) was proposed based on the maximum a posteriori Bayesian method (MAPB), and the algorithm was applied to the patient's computed tomography (CT) scan. The results indicated that in terms of curative effect, the number of complete remission (CR), partial remission (PR) cases, effective rate, and clinical benefit rate of the test group was significantly higher than those of the control group. The number of progress disease (PD) cases was significantly lower than that of the control group (P < 0.05). The disease progression time of the test group patients was 6.2 months, and the disease progression time of the control group patients was 3.7 months (P < 0.05). The test group patients had 8 cases of bone marrow suppression and gastrointestinal reactions after treatment. In the test group, there were 8 cases of bone marrow suppression, 9 cases of gastrointestinal reaction, 3 cases of fever, 4 cases of pain, and 2 cases of hair loss. The patients in the control group were complicated with bone marrow suppression in 14 cases, gastrointestinal reaction in 17 cases, fever in 5 cases, pain in 4 cases, and hair loss in 6 cases. The difference was statistically significant (P < 0.05). It showed that zoledronic acid combined with chemotherapy could effectively improve the treatment efficiency and clinical benefit rate of patients with lung cancer spinal metastases, prolong the progression of the disease, reduce the degree of bone tissue damage, and would not increase chemotherapy adverse events.

[89Zr]-Pertuzumab PET Imaging Reveals Paclitaxel Treatment Efficacy Is Positively Correlated with HER2 Expression in Human Breast Cancer Xenograft Mouse Models

Paclitaxel (PTX) treatment efficacy varies in breast cancer, yet the underlying mechanism for variable response remains unclear. This study evaluates whether human epidermal growth factor receptor 2 (HER2) expression level utilizing advanced molecular positron emission tomography (PET) imaging is correlated with PTX treatment efficacy in preclinical mouse models of HER2+ breast cancer. HER2 positive (BT474, MDA-MB-361), or HER2 negative (MDA-MB-231) breast cancer cells were subcutaneously injected into athymic nude mice and PTX (15 mg/kg) was administrated. In vivo HER2 expression was quantified through [89Zr]-pertuzumab PET/CT imaging. PTX treatment response was quantified by [18F]-fluorodeoxyglucose ([18F]-FDG) PET/CT imaging. Spearman's correlation, Kendall's tau, Kolmogorov-Smirnov test, and ANOVA were used for statistical analysis. [89Zr]-pertuzumab mean standard uptake values (SUVmean) of BT474 tumors were 4.9 ± 1.5, MDA-MB-361 tumors were 1.4 ± 0.2, and MDA-MB-231 (HER2-) tumors were 1.1 ± 0.4. [18F]-FDG SUVmean changes were negatively correlated with [89Zr]-pertuzumab SUVmean (r = -0.5887, p = 0.0030). The baseline [18F]-FDG SUVmean was negatively correlated with initial [89Zr]-pertuzumab SUVmean (r = -0.6852, p = 0.0002). This study shows PTX treatment efficacy is positively correlated with HER2 expression level in human breast cancer mouse models. Molecular imaging provides a non-invasive approach to quantify biological interactions, which will help in identifying chemotherapy responders and potentially enhance clinical decision-making.